CCT128930AKT inhibitor CAS# 885499-61-6 |
- GDC-0068 (RG7440)
Catalog No.:BCC1271
CAS No.:1001264-89-6
- AT7867 dihydrochloride
Catalog No.:BCC1378
CAS No.:1431697-86-7
- A-443654
Catalog No.:BCC1321
CAS No.:552325-16-3
- A-674563
Catalog No.:BCC3903
CAS No.:552325-73-2
- AT7867
Catalog No.:BCC2536
CAS No.:857531-00-1
- 10-DEBC hydrochloride
Catalog No.:BCC7409
CAS No.:925681-41-0
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 885499-61-6 | SDF | Download SDF |
| PubChem ID | 17751819 | Appearance | Powder |
| Formula | C18H20ClN5 | M.Wt | 341.84 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 36.67 mg/mL (107.27 mM; Need ultrasonic) | ||
| Chemical Name | 4-[(4-chlorophenyl)methyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-amine | ||
| SMILES | C1CN(CCC1(CC2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4 | ||
| Standard InChIKey | RZIDZIGAXXNODG-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C18H20ClN5/c19-14-3-1-13(2-4-14)11-18(20)6-9-24(10-7-18)17-15-5-8-21-16(15)22-12-23-17/h1-5,8,12H,6-7,9-11,20H2,(H,21,22,23) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | CCT128930 is a potent, ATP-competitive and selective inhibitor of Akt2 with IC50 of 6 nM. | |||||
| Targets | Akt2 | p70 S6K | PKA | |||
| IC50 | 6 nM | 120 nM | 168 nM | |||
CCT128930 Dilution Calculator
CCT128930 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.9253 mL | 14.6267 mL | 29.2535 mL | 58.5069 mL | 73.1336 mL |
| 5 mM | 0.5851 mL | 2.9253 mL | 5.8507 mL | 11.7014 mL | 14.6267 mL |
| 10 mM | 0.2925 mL | 1.4627 mL | 2.9253 mL | 5.8507 mL | 7.3134 mL |
| 50 mM | 0.0585 mL | 0.2925 mL | 0.5851 mL | 1.1701 mL | 1.4627 mL |
| 100 mM | 0.0293 mL | 0.1463 mL | 0.2925 mL | 0.5851 mL | 0.7313 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
CCT128930 is a potent, selective, novel and ATP-competitive inhibitor for AKT2 (IC50= 6 nM). It also has 28-fold and 20-fold selectivity over PKA kinase (IC50= 168 nM) and p70S6K (IC50= 120 nM), respectively.
Akt (protein kinase B) is a serine/threonine-specific protein kinase that plays a key role in multiple cellular processes such as glucose metabolism, apoptosis, cell proliferation, transcription and cell migration.
In multi tumor cell line, CCT128930 showed antiproliferative effect and blocked the phosphorylation of various Akt substrates. In PTEN-null human glioblastoma cells (U87MG), CCT128930 treatment led to a G1 arrest associated with Akt pathway suppression. [1]
In U87MG tumor xenografts, CCT128930 inhibited the phosphorylation of Akt downstream biomarkers. In U87MG, HER-2 positive and IK3CA-mutant BT474 human breast cancer xenografts, antitumor activity were recorded as tumor volume decreased. CCT128930-treated mouse whisker folliciles in vivo and human hair follicles treated ex vivo exerted prominent reduction in pThr246 PRAS40. [1]
Reference:
1. Yap TA, Walton MI, Hunter LJ et al. Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930. Mol Cancer Ther. 2011 Feb;10(2):360-71.
- Minumicrolin
Catalog No.:BCN4433
CAS No.:88546-96-7
- HJC 0350
Catalog No.:BCC6302
CAS No.:885434-70-8
- MK-8745
Catalog No.:BCC3994
CAS No.:885325-71-3
- Kongensin A
Catalog No.:BCN4432
CAS No.:885315-96-8
- W-13 hydrochloride
Catalog No.:BCC6620
CAS No.:88519-57-7
- Rosamultin
Catalog No.:BCN7391
CAS No.:88515-58-6
- LY 2389575 hydrochloride
Catalog No.:BCC7985
CAS No.:885104-09-6
- GW9508
Catalog No.:BCC1102
CAS No.:885101-89-3
- Dichotomitin
Catalog No.:BCN8524
CAS No.:88509-91-5
- ARRY 520 trifluoroacetate
Catalog No.:BCC2391
CAS No.:885060-09-3
- ARRY-520 R enantiomer
Catalog No.:BCC1368
CAS No.:885060-08-2
- Benzotetramisole
Catalog No.:BCC8861
CAS No.:885051-07-0
- 5'-O-Acetyljuglanin
Catalog No.:BCN6846
CAS No.:885697-82-5
- c-FMS inhibitor
Catalog No.:BCC1472
CAS No.:885704-21-2
- Fmoc-ε-Acp-OH
Catalog No.:BCC3206
CAS No.:88574-06-5
- Isomexoticin
Catalog No.:BCN4434
CAS No.:88585-86-8
- LY2119620
Catalog No.:BCC5564
CAS No.:886047-22-9
- Chrysin 7-O-beta-gentiobioside
Catalog No.:BCN2943
CAS No.:88640-89-5
- Cerebroside B
Catalog No.:BCN4435
CAS No.:88642-46-0
- Apogossypolone (ApoG2)
Catalog No.:BCC2237
CAS No.:886578-07-0
- 11-Hydroxy-sugiol
Catalog No.:BCN2510
CAS No.:88664-08-8
- 14-Deoxycoleon U
Catalog No.:BCN4796
CAS No.:88664-09-9
- 8-Epideoxyloganic acid
Catalog No.:BCN6576
CAS No.:88668-99-9
- Liranaftate
Catalog No.:BCC4672
CAS No.:88678-31-3
CCT128930 induces cell cycle arrest, DNA damage, and autophagy independent of Akt inhibition.[Pubmed:24793486]
Biochimie. 2014 Aug;103:118-25.
PI3K/Akt/mTOR pathway plays an important role in tumor progression and anti-cancer drug resistance. The aim of the present study is to determine the antitumor effect of CCT128930, a novel small molecule inhibitor of Akt, in the HepG2 hepatoma cancer cells. Our results showed that at low concentrations, CCT128930 increased, but not inhibited, the phosphorylation of Akt in HepG2 and A549 cells. CCT128930 inhibited cell proliferation by inducing cell cycle arrest in G1 phase through downregulation of cyclinD1 and Cdc25A, and upregulation of p21, p27 and p53. A higher dose (20 muM) of CCT128930 triggered cell apoptosis with activation of caspase-3, caspase-9, and PARP. Treatment with CCT128930 increased phosphorylation of ERK and JNK in HepG2 cells. CCT128930 activated DNA damage response of HepG2 cell characterized by phosphorylation of H2AX, ATM (ataxia-telangiectasia mutated), Chk1 and Chk2. Upon exposure to CCT128930 at a higher concentration, HepG2 cells exhibited autophagy was accompanied by an increase the levels of LC3-II and Beclin-1. Blocking autophagy using chloroquine magnified CCT128930-induced apoptotic cell death and the phosphorylation of H2AX. The results in this study have advanced our current understandings of the anti-cancer mechanisms of CCT128930 in cancer cells.
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.[Pubmed:21191045]
Mol Cancer Ther. 2011 Feb;10(2):360-71.
AKT is frequently deregulated in cancer, making it an attractive anticancer drug target. CCT128930 is a novel ATP-competitive AKT inhibitor discovered using fragment- and structure-based approaches. It is a potent, advanced lead pyrrolopyrimidine compound exhibiting selectivity for AKT over PKA, achieved by targeting a single amino acid difference. CCT128930 exhibited marked antiproliferative activity and inhibited the phosphorylation of a range of AKT substrates in multiple tumor cell lines in vitro, consistent with AKT inhibition. CCT128930 caused a G(1) arrest in PTEN-null U87MG human glioblastoma cells, consistent with AKT pathway blockade. Pharmacokinetic studies established that potentially active concentrations of CCT128930 could be achieved in human tumor xenografts. Furthermore, CCT128930 also blocked the phosphorylation of several downstream AKT biomarkers in U87MG tumor xenografts, indicating AKT inhibition in vivo. Antitumor activity was observed with CCT128930 in U87MG and HER2-positive, PIK3CA-mutant BT474 human breast cancer xenografts, consistent with its pharmacokinetic and pharmacodynamic properties. A quantitative immunofluorescence assay to measure the phosphorylation and total protein expression of the AKT substrate PRAS40 in hair follicles is presented. Significant decreases in pThr246 PRAS40 occurred in CCT128930-treated mouse whisker follicles in vivo and human hair follicles treated ex vivo, with minimal changes in total PRAS40. In conclusion, CCT128930 is a novel, selective, and potent AKT inhibitor that blocks AKT activity in vitro and in vivo and induces marked antitumor responses. We have also developed a novel biomarker assay for the inhibition of AKT in human hair follicles, which is currently being used in clinical trials.
